ACCEDI

Per proseguire, inserisci il nome utente (mail di registrazione) e la password del tuo account AccMed Online.

REGISTRATI

Se non hai un account AccMed Online, registrati ora gratuitamente.

AccMed Online è l’account gratuito che permette di iscriversi e partecipare alle attività formative (su fad.accmed.org) e di accedere agli altri servizi digitali di Accademia Nazionale di Medicina.

Da congressi e letteratura

IN PRIMO PIANO

20 Dicembre 2023

HIGHLIGHTS from ASH 2023

A cura di Pier Luigi Zinzani

AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2022

[NEW]

Slide kit - Update da ASH 2022 - A cura di Pier Luigi Zinzani (BO)

Meeting Abstracts

Abstracts - CAR-T Focus

EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2022

Slide kit - Update da EHA 2022

Abstract EHA2022

Abstracts – CAR-T focus

EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2021

Abstract EHA2021

Abstracts – CAR-T focus

Abstracts – Tisagenlecleucel focus

16th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA, VIRTUAL EDITION - 2021

Meeting Abstracts

Abstracts - CAR-T Focus

Abstracts - Tisagenlecleucel Focus

AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2021

Commento video: Le novità più rilevanti per le CAR-T nel DLBCL

Meeting Abstracts

Abstracts - CAR-T Focus

Abstracts – Tisagenlecleucel Focus

EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2020

Abstract Book

Open Access Library

Educational Updates in Hematology Book

Guidance Document: The process of CAR-T cell therapy in Europe

THE VIDEO JOURNAL OF HEMATOLOGICAL ONCOLOGY

[NEW]

4th International Workshop on CAR-T (iwCAR-T)

EBMT Meeting 2022 focus su CAR-T

EBMT-EHA European CAR T-cell Meeting 2022

International Workshop on CAR-T (iwCAR-T) 2021

The Video Journal of Hematological Oncology - CAR-T Focus

THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION

The EBMT/EHA CAR-T Cell Handbook

DA ACCADEMIA NAZIONALE DI MEDICINA

Locke FL, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Bishop MR, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Highlights 2020 su CAR-T - Alice Di Rocco

Esperienza dell’ematologia di Monza nelle LLA - Adriana Balduzzi

Ramos CA, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma

Munshi NC, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

BEST PRACTICE & GUIDELINES

Best Practice Recommendations Of The EBMT

National Comprehensive Cancer Network

National Comprehensive Cancer Network - Immunotherapy Side EffectsCAR T-Cell Therapy

©Accademia Nazionale di Medicina | Webmaster | Privacy policy | Realizzato da